Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis
1
Issued Date
2022-08-01
Resource Type
ISSN
09462716
eISSN
14321440
Scopus ID
2-s2.0-85134622771
Pubmed ID
35861882
Journal Title
Journal of Molecular Medicine
Volume
100
Issue
8
Start Page
1145
End Page
1157
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Molecular Medicine Vol.100 No.8 (2022) , 1145-1157
Suggested Citation
Yangngam S., Prasopsiri J., Hatthakarnkul P., Thongchot S., Thuwajit P., Yenchitsomanus P.t., Edwards J., Thuwajit C. Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis. Journal of Molecular Medicine Vol.100 No.8 (2022) , 1145-1157. 1157. doi:10.1007/s00109-022-02228-w Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/83656
Title
Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis
Author's Affiliation
Other Contributor(s)
Abstract
Nucleolin (NCL) is a multifunctional protein expressed in the nucleus, cytoplasm, and cell membrane. Overexpression of NCL has a controversial role as a poor prognostic marker in cancers. In this study, a meta-analysis was performed to evaluate the prognostic value of NCL in different subcellular localizations (cytoplasmic (CyNCL) and nuclear (NuNCL)) across a range of cancers. PubMed was searched for relevant publications. Data were extracted and analyzed from 12 studies involving 1221 patients with eight cancer types. The results revealed high total NCL was significantly associated with poor overall survival (OS) (HR = 2.85 (1.94, 4.91), p < 0.00001, I2 = 59%) and short disease-free survival (DFS) (HR = 3.57 (2.76, 4.62), p < 0.00001, I2 = 2%). High CyNCL was significantly associated with poor OS (HR = 4.32 (3.01, 6.19), p < 0.00001, I2 = 0%) and short DFS (HR = 3.00 (2.17, 4.15), p < 0.00001, I2 = 0%). In contrast, high NuNCL correlated with increased patient OS (HR = 0.42 (0.20, 0.86), p = 0.02, I2 = 66%), with no significant correlation to DFS observed (HR = 0.46 (0.19, 1.14), p = 0.09, I2 = 57%). This study supports the role of subcellular NCL as a poor prognostic cancer biomarker.